Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
Company has changed auditors in a bid to comply with U.S. law and avoid a potential forced delisting from the Nasdaq Key Takeaways: BeiGene has switched auditors for its New…
RELATED ARTICLES
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
Heated market for dueling blood cancer drugs lands BeiGene in court
BGNE.US 6160.HK
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
FAST NEWS: Beigene stock falls after Novartis terminates partnership
BGNE.US 6160.HK
-
Everest reaches new heights on growing drug sales
1952.HK
Discover hidden China stock gems in our weekly newsletter